Jim Cornall

biotech

Investigational treatment of autosomal dominant polycystic kidney disease receives orphan drug designation

biotech

World’s first gene-editing therapy for hyperlipidemia

biotech

Positive results for Lilly obesity drug

biotech

“Foundational moment for in vivo cell therapy”

biotech

Cooperative motor proteins kill cancer cells when dual-inhibited

biotech

SanegeneBio announces collaboration with Lilly

biotech

Amgen reveals cardiovascular drug results

biotech

Pila Pharma’s capital raise oversubscribed by 293% to fund obesity studies